Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) traded down 0.5% during trading on Tuesday . The company traded as low as $1.8077 and last traded at $1.81. 4,444 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 26,053 shares. The stock had previously closed at $1.82.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on IPHA shares. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of Innate Pharma in a research note on Wednesday, October 29th. Leerink Partnrs downgraded Innate Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 18th. HC Wainwright set a $5.00 price objective on Innate Pharma and gave the company a “buy” rating in a research note on Wednesday, October 29th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $10.00) on shares of Innate Pharma in a research report on Thursday, September 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Innate Pharma presently has an average rating of “Hold” and a consensus price target of $5.00.
Read Our Latest Research Report on Innate Pharma
Innate Pharma Stock Down 0.5%
Innate Pharma Company Profile
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Featured Stories
- Five stocks we like better than Innate Pharma
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
